Mesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%

MT Newswires Live

2025/07/18

Mesoblast (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.

The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.

The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.

The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.

Mesoblast's shares soared 25% in early trading on Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552300024"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552300024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552300024?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552300024","market":"hk","top_or_hot":-1,"title":"Mesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MESO\">Mesoblast</a> (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.</p><p>The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.</p><p>The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.</p><p>The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.</p><p>Mesoblast's shares soared 25% in early trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-18 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MESO\">Mesoblast</a> (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.</p><p>The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.</p><p>The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.</p><p>The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.</p><p>Mesoblast's shares soared 25% in early trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2552300024","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552300024","pubTimestamp":1752801415,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.Mesoblast's shares soared 25% in early trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD","MESO":"Mesoblast Limited"},"translate_title":"Mesoblast报告Ryoncil产品销售总收入超过1300万美元；股价飙升25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1,"MSB.AU":0.9},"content_text":"Mesoblast (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.Mesoblast's shares soared 25% in early trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}